Parvin Milani-Zakeri

Dr. Parvin Milani-Zakeri


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2015 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
NNNeda Naseri
Neda Naseri
HVHadi Valizadeh
Hadi Valizadeh
PMParvin Milani-Zakeri
Parvin Milani-Zakeri
Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application

1 May 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Seyed hossein KiaieSeyed hossein Kiaie
Seyed hossein Kiaie
SMSolmaz Mojarad-Jabali
Solmaz Mojarad-Jabali
FKFarnaz Khaleseh
Farnaz Khaleseh
SASaeideh Allahyari
Saeideh Allahyari
ETElham Taheri
Elham Taheri
HVHadi Valizadeh
Hadi Valizadeh

23 March 2020 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
FZFahimeh Zahednezhad
Fahimeh Zahednezhad
PMParvin Milani-Zakeri
Parvin Milani-Zakeri
JMJavid Shahbazi Mojarrad
Javid Shahbazi Mojarrad
HVHadi Valizadeh
Hadi Valizadeh
Introduction: Cisplatin has been indicated for several malignancies all over the world for many years. Increasing patient tolerance for high dose of chemotherapeutics and reducing side effects has been granted by drug encapsulated liposomal systems. There have been much efforts for improving Cisplatin delivery to the site of action via liposomes both in research and clinical trials such as SPI-077®, Liplacis®, and Lipoplatin®. Areas covered: In this review, we have discussed about Cisplatin and its liposomal formulations, focusing on different preparation methods and analysis approaches such as atomic absorption, mass spectroscopy, UV, electrochemical methods, and emphasizing on HPLC as one of the accurate and specific methods for determination of Cisplatin species and also measurement of total platinum by derivation. Expert Opinion: Liposome of Cisplatin have offered potential beneficial aspects over Cisplatin formulation. However, there are several challenges in preparing and analysis of Cisplatin liposomes due to Cisplatin’s great reactivity, formation of several species, high affinity to bio-elements, insufficient release at the tumor site, and inefficient loading. Cisplatin resistance is another challenge which should be prevented by higher loading capacity. Charge dependent interactions should also be highly considered especially in the preparation step.

18 April 2019 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
SASaeideh Allahyari
Saeideh Allahyari
FTFrancesco Trotta
Francesco Trotta
HVHadi Valizadeh
Hadi Valizadeh
MJMitra Jelvehgari
Mitra Jelvehgari
PMParvin Milani-Zakeri
Parvin Milani-Zakeri
Introduction: In recent years, new drug delivery systems have attempted to overcome the undesirable pharmacokinetic problems of various drugs. Among them, cyclodextrin nanosponges (CDNSs) attract great attention from researchers for solving major bioavailability problems such as inadequate solubility, poor dissolution rate, and the limited stability of some agents, as well as increasing their effectiveness and decreasing unwanted side effects. This novel system can also be prepared as different dosage forms. Areas covered: This review will give an insight into the effects of CDNSs on the pharmacokinetic parameters and permeability of active agents. Different classes of drugs delivered by this system are mentioned and we designate which CD is used most widely in their production process. We also inform why this carrier can be introduced as a versatile carrying system in pharmaceutical fields. Registered patents about this novel system in various fields are also mentioned. Expert opinion: The readers will be informed on CDNSs as a novel carrier especially for the delivery of drugs. Versatile characteristics and applications of them can also be known by this review. Finally, CDNSs may be introduced as a remarkable vehicle in the pharmaceutical market in coming years.

1 July 2020 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
SMSomayeh Mahdinloo
Somayeh Mahdinloo
Seyed hossein KiaieSeyed hossein Kiaie
Seyed hossein Kiaie
AAAla Amiri
Ala Amiri
SHSalar Hemmati
Salar Hemmati
HVHadi Valizadeh
Hadi Valizadeh
PMParvin Milani-Zakeri
Parvin Milani-Zakeri
Liver fibrosis results from chronic damages together with an accumulation of extracellular matrix, and no specific medical therapy is approved for that until now. Due to liver metabolic capacity for drugs, the fragility of drugs, and the presence of insurmountable physiological obstacles in the way of targeting, the development of efficient drug delivery systems for anti-fibrotics seems vital. We have explored articles with a different perspective on liver fibrosis over the two decades, then collected and summarized the information by providing corresponding in vitro and in vivo cases. We have discussed the mechanism of hepatic fibrogenesis with different ways of fibrosis induction in animals. Furthermore, the critical chemical and herbal anti-fibrotics, biological molecules such as micro-RNAs, siRNAs, and growth factors, which can affect cell division and differentiation, are mentioned. Likewise, drug and gene delivery and therapeutic systems on in vitro and in vivo models are summarized in the data tables. This review article enlightens recent advances in emerging drugs and nanocarriers and represents perspectives on targeting strategies employed in liver fibrosis treatment.

1 February 2022 in Polymers
Verified
Journal Article
Open access
PDF file
Yousef Khazaei MonfaredYousef Khazaei Monfared
Yousef Khazaei Monfared
MMMohammad Mahmoudian
Mohammad Mahmoudian
Claudio CeconeClaudio Cecone
Claudio Cecone
Fabrizio CalderaFabrizio Caldera
Fabrizio Caldera
PMParvin Milani-Zakeri
Parvin Milani-Zakeri
Adrián MatencioAdrián Matencio
Adrián Matencio
The great variability of cancer types demands novel drugs with broad spectrum, this is the case of Nisin, a polycyclic antibacterial peptide that recently has been considered for prevention of cancer cells growth. As an accepted food additive, this drug would be very useful for intestinal cancers, but the peptide nature would make easier its degradation by digestion procedures. For that reason, the aim of present study to investigate the protective effect of two different β-cyclodextrin-based nanosponges (carbonyl diimidazole and pyromellitic dianhydride) and their anti-cancer enhancement effect of Nisin-Z encapsulated with against colon cancer cells (HT-29). To extend its possible use, a comparison with breast (MCF-7) cancer cell was carried out. The physicochemical properties, loading efficiency, and release kinetics of Nisin complex with nanosponges were studied. Then, tricin-SDS-PAGE electrophoresis was used to understand the effect of NSs on stability of Nisin-Z in the presence of gastric peptidase pepsin. In addition, the cytotoxicity and cell membrane damage of Nisin Z were evaluated by using the MTT and LDH assay, which was complemented via Annexin-V/ Propidium Iodide (PI) by using flowcytometry. CD-NS are able to complex Nisin-Z with an encapsulation efficiency around 90%. A protective effect of Nisin-Z complexed with CD-NSs was observed in presence of pepsin. An increase in the percentage of apoptotic cells was observed when the cancer cells were exposed to Nisin Z complexed with nanosponges. Interestingly, Nisin Z free and loaded on PMDA/CDI-NSs is more selectively toxic towards HT-29 cells than MCF-7 cancer cells. These results indicated that nanosponges might be good candidates to protect peptides and deliver drugs against intestinal cancers.